Literature DB >> 19385447

Prevalence of cardiomyopathy in Duchenne and Becker's muscular dystrophy.

Ambreen Sultan1, Mohammad Fayaz.   

Abstract

BACKGROUND: Cardiac assessment was not done routinely in Duchenne (DMD) and Becker muscular dystrophy (BMD) patients in Northern region of England while evidence was gathering on progressive cardiomyopathy in these patients. We wanted to find out the prevalence, progression and clinical features of cardiac involvement in Duchenne and Becker muscular dystrophy.
METHODS: It is a retrospective review of clinical, electrocardiographic and echocardiographic assessments.
RESULTS: The notes of 52 Duchenne and Becker muscular dystrophy patients were reviewed out of which 32 had DMD, 6 had Intermediate muscular dystrophy (IMD) and 14 had BMD. Prevalence of preclinical and clinically evident cardiac involvement was 88.4% in DMD and BMD patients. Sixty nine% of patients had clinically evident cardiac involvement but only four patients had cardiac symptoms in the form of palpitations, out of which two were due to respiratory dysfunction and others was due to cardiac failure. Clinical examination of the rest of all of the patients was unremarkable. Electrocardiogram was abnormal in 88.4% of patients. Conduction defects were found in 19.4% of patients. Echocardiogram was abnormal in 80.7% of patients but all were poor echo subjects including those who had normal echocardiogram.
CONCLUSIONS: Though most patients were asymptomatic, a high percentage had evidence of preclinical and clinically evident cardiac involvement. So in all patients with Xp21 linked muscular dystrophy a routine baseline cardiac assessment should be done at the age of 10 years and reviewed after intervals of one to two years.

Entities:  

Mesh:

Year:  2008        PMID: 19385447

Source DB:  PubMed          Journal:  J Ayub Med Coll Abbottabad        ISSN: 1025-9589


  8 in total

1.  Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs.

Authors:  Deborah M Fine; Jin-Hong Shin; Yongping Yue; Dietrich Volkmann; Stacey B Leach; Bruce F Smith; Mark McIntosh; Dongsheng Duan
Journal:  Neuromuscul Disord       Date:  2011-05-13       Impact factor: 4.296

2.  Proteomic Profiling of the Dystrophin-Deficient MDX Heart Reveals Drastically Altered Levels of Key Metabolic and Contractile Proteins.

Authors:  Caroline Lewis; Harald Jockusch; Kay Ohlendieck
Journal:  J Biomed Biotechnol       Date:  2010-05-23

3.  Coronary adventitial cells are linked to perivascular cardiac fibrosis via TGFβ1 signaling in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Nicholas Ieronimakis; Aislinn L Hays; Kajohnkiart Janebodin; William M Mahoney; Jeremy S Duffield; Mark W Majesky; Morayma Reyes
Journal:  J Mol Cell Cardiol       Date:  2013-08-01       Impact factor: 5.000

4.  Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.

Authors:  Corinne A Betts; Amer F Saleh; Carolyn A Carr; Suzan M Hammond; Anna M L Coenen-Stass; Caroline Godfrey; Graham McClorey; Miguel A Varela; Thomas C Roberts; Kieran Clarke; Michael J Gait; Matthew J A Wood
Journal:  Sci Rep       Date:  2015-03-11       Impact factor: 4.379

5.  Characterization and Functional Analysis of Extracellular Vesicles and Muscle-Abundant miRNAs (miR-1, miR-133a, and miR-206) in C2C12 Myocytes and mdx Mice.

Authors:  Yasunari Matsuzaka; Jun Tanihata; Hirofumi Komaki; Akihiko Ishiyama; Yasushi Oya; Urs Rüegg; Shin-Ichi Takeda; Kazuo Hashido
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

Review 6.  Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy.

Authors:  Tirsa L E van Westering; Corinne A Betts; Matthew J A Wood
Journal:  Molecules       Date:  2015-05-15       Impact factor: 4.411

7.  PDGFRα signalling promotes fibrogenic responses in collagen-producing cells in Duchenne muscular dystrophy.

Authors:  Nicholas Ieronimakis; Aislinn Hays; Amalthiya Prasad; Kajohnkiart Janebodin; Jeremy S Duffield; Morayma Reyes
Journal:  J Pathol       Date:  2016-10-20       Impact factor: 7.996

8.  Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.

Authors:  Corinne A Betts; Graham McClorey; Richard Healicon; Suzan M Hammond; Raquel Manzano; Sofia Muses; Vicky Ball; Caroline Godfrey; Thomas M Merritt; Tirsa van Westering; Liz O'Donovan; Kim E Wells; Michael J Gait; Dominic J Wells; Damian Tyler; Matthew J Wood
Journal:  Hum Mol Genet       Date:  2019-02-01       Impact factor: 6.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.